These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 10037017

  • 1. Survival in a patient with polycythaemia vera for over thirty years: implications for treatment decisions in younger patients.
    Samuelsson J.
    Leuk Lymphoma; 1998 Dec; 32(1-2):195-8. PubMed ID: 10037017
    [Abstract] [Full Text] [Related]

  • 2. Plasma erythropoietin concentrations in polycythaemia vera with special reference to myelosuppressive therapy.
    Andréasson B, Carneskog J, Lindstedt G, Lundberg PA, Swolin B, Wadenvik H, Kutti J.
    Leuk Lymphoma; 2000 Mar; 37(1-2):189-95. PubMed ID: 10721786
    [Abstract] [Full Text] [Related]

  • 3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 4. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J, Román Barbero A, Nevado Reviriego I.
    Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
    [No Abstract] [Full Text] [Related]

  • 5. Polycythemia vera: a review.
    Golden C.
    Clin J Oncol Nurs; 2003 Jun; 7(5):553-6. PubMed ID: 14603552
    [Abstract] [Full Text] [Related]

  • 6. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 7. [Polycythaemia vera--diagnosis and therapy].
    Lechner K, Geissler K, Gisslinger H.
    Wien Klin Wochenschr; 1999 Aug 20; 111(15):582-9. PubMed ID: 10483672
    [Abstract] [Full Text] [Related]

  • 8. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y, Rain JD, Dresch C, Goguel A, Lejeune F, Echard M, Grange MJ.
    Leuk Lymphoma; 1996 Sep 20; 22 Suppl 1():111-9. PubMed ID: 8951781
    [Abstract] [Full Text] [Related]

  • 9. The choice of treatment in polycythaemia vera.
    Najean Y, Dresch C.
    Drugs Exp Clin Res; 1986 Sep 20; 12(1-3):177-80. PubMed ID: 3525073
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR.
    Semin Hematol; 1986 Apr 20; 23(2):132-43. PubMed ID: 3704665
    [Abstract] [Full Text] [Related]

  • 11. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients.
    Herishanu Y, Lishner M, Bomstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, Amiel A.
    Cancer Genet Cytogenet; 2001 Jul 15; 128(2):154-7. PubMed ID: 11463455
    [Abstract] [Full Text] [Related]

  • 12. Survival of patients with polycythemia vera on busulfan or 32P.
    Mathé G.
    N Engl J Med; 1978 Feb 02; 298(5):279. PubMed ID: 619270
    [No Abstract] [Full Text] [Related]

  • 13. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
    Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martínez C, Albors M, García F, Burgaleta C, Besses C, Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas.
    Haematologica; 2017 Jan 02; 102(1):103-109. PubMed ID: 27686377
    [Abstract] [Full Text] [Related]

  • 14. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI.
    Eur J Haematol; 2000 Jul 02; 65(1):1-7. PubMed ID: 10914933
    [Abstract] [Full Text] [Related]

  • 15. Polycythaemia vera treated with radioactive phosphorus.
    FRANK T.
    Med J Aust; 1952 Feb 16; 1(7):232-3. PubMed ID: 14918721
    [No Abstract] [Full Text] [Related]

  • 16. Polycythemia vera: a retrospective and reprise.
    Berlin NI, Wasserman LR.
    J Lab Clin Med; 1997 Oct 16; 130(4):365-73. PubMed ID: 9358074
    [Abstract] [Full Text] [Related]

  • 17. Clinical and laboratory assessment and therapeutic problems in longstanding polycythaemia vera.
    Rain JD.
    Nouv Rev Fr Hematol (1978); 1994 Apr 16; 36(2):197-203. PubMed ID: 8036142
    [Abstract] [Full Text] [Related]

  • 18. Unanswered questions in polycythaemia vera.
    Finazzi G.
    Eur J Haematol Suppl; 2007 Oct 16; (68):18-21. PubMed ID: 17727560
    [No Abstract] [Full Text] [Related]

  • 19. Busulfan versus 32P in polycythaemia vera.
    Zittoun R.
    Drugs Exp Clin Res; 1986 Oct 16; 12(1-3):283-5. PubMed ID: 3525077
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.